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Abstract: 
Objective  
To evaluate the cost-effectiveness of implantable cardioverter-defibrillators 
(ICD), cardiac resynchronisation therapy pacemakers (CRT-P) and 
combination therapy (CRT-D) in patients with heart failure with reduced 
ejection fraction based on a range of clinical characteristics.  
Methods  
Individual patient data from 13 randomised trials were used to inform a 
decision analytic model. A series of regression equations were used to 
predict baseline all-cause mortality, hospitalisation rates and health related 
quality of life (HRQoL) and device-related treatment effects. Clinical 
variables used in these equations were age, QRS duration, NYHA class, 
ischemic aetiology, and LBBB. A UK NHS perspective and a lifetime time 
horizon were used. Benefits were expressed as quality adjusted life years 
(QALYs). Results were reported for 24 subgroups based on LBBB status, 
QRS duration and NYHA class.  
Results  
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At a threshold of £30,000 per QALY gained, CRT-D was cost-effective in 10 
of the 24 subgroups including all LBBB morphology patients with NYHA 
I/III/III. ICD is cost-effective for all non-NYHA IV patients with QRS 
duration <120ms and for NYHA I/II non-LBBB morphology patients with 
QRS duration between 120 and 149ms. CRT-P was also cost-effective in all 
NYHA III/IV patients with QRS duration >120ms. Device therapy is cost-
effective in most patient groups with LBBB at a threshold of £20,000 per 
QALY gained. Results were robust to altering key model parameters.  
Conclusions  
At a threshold of £30,000 per QALY gained, CRT-D is cost-effective in a far 
wider group than previously recommended in the UK. In some subgroups 
ICD and CRT-P remain the cost-effective choice.  
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Abstract (250 words) 
 
Objective 
To evaluate the cost-effectiveness of implantable cardioverter-defibrillators (ICD), cardiac 
resynchronisation therapy pacemakers (CRT-P) and combination therapy (CRT-D) in patients 
with heart failure with reduced ejection fraction based on a range of clinical characteristics. 
Methods 
Individual patient data from 13 randomised trials were used to inform a decision analytic model. 
A series of regression equations were used to predict baseline all-cause mortality, 
hospitalisation rates and health related quality of life and device-related treatment effects. 
Clinical variables used in these equations were age, QRS duration, NYHA class, ischemic 
aetiology, and LBBB. A UK NHS perspective and a lifetime time horizon were used. Benefits 
were expressed as quality adjusted life years (QALYs). Results were reported for 24 subgroups 
based on LBBB status, QRS duration and NYHA class.  
Results 
At a threshold of £30,000 per QALY gained, CRT-D was cost-effective in 10 of the 24 
subgroups including all LBBB morphology patients with NYHA I/II/III. ICD is cost-effective for all 
non-NYHA IV patients with QRS duration <120ms and for NYHA I/II non-LBBB morphology 
patients with QRS duration between 120 and 149ms. CRT-P was also cost-effective in all NYHA 
III/IV patients with QRS duration >120ms. Device therapy is cost-effective in most patient 
groups with LBBB at a threshold of £20,000 per QALY gained. Results were robust to altering 
key model parameters. 
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Conclusions 
At a threshold of £30,000 per QALY gained, CRT-D is cost-effective in a far wider group than 
previously recommended in the UK. In some subgroups ICD and CRT-P remain the cost-
effective choice.  
Keywords 
Cardiac Resynchronisation, Implantable Cardioverter Defibrillator, Cost-effectiveness, Cost-
utility, CRT, ICD 
 
Key questions 
What is already known about this subject? 
Clinical guidelines on ICD/CRT in HF make recommendations for ICD, CRT-P and CRT-D 
based on a range of clinical parameters. These include NYHA class, LVEF, ischaemic aetiology 
status, QRS duration, and presence or absence of either AF or LBBB. ICD and CRT therapy are 
not indicated in all patient groups of interest. 
ICD, CRT-P and CRT-D have been shown to represent a cost-effective use of UK health care 
expenditure when compared to medical therapy, and when evaluated in patient groups 
determined by individual trial inclusion criteria. 
What does this study add? 
We have compared the devices to each other, as well as no device therapy in a much wider set 
of patients than has previously been evaluated in order to provide an answer to the question ‘in 
which patients are ICD/CRT-P/CRT-D cost-effective?’. 
Data from multiple RCTs rather than single studies were used to inform the cost-effectiveness 
analysis hence results are more reflective of the totality of the clinical data. Results are stratified 
by a series of commonly used clinical parameters and present health care decision makers with 
much more information than was previously available. 
Device therapy is cost effective at a threshold of £30,000 per QALY gained in all sub-groups 
examined. CRT-D is cost effective in 10 of the 24 subgroups, and is cost effective for all LBBB 
morphology patients with NYHA I-III. ICDs are cost effective for all NYHA I-III patients with a 
QRS duration <120ms and for NYHA I-II patients with non-LBBB morphology and a QRS 
duration between 120 and 149ms. CRT-P is cost-effective for all NYHA IV patients evaluated. 
How might this impact on clinical practice? 
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The results from our work will allow health care decision makers to make more informed 
decisions on which devices to offer patients taking in to account both clinical and economic 
factors. 
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Introduction 
In addition to guideline directed medical therapy, implantable cardiac devices have an 
established role in the treatment of heart failure with reduced ejection fraction (HFrEF). 
International clinical guidelines1-3 make recommendations for implantable cardioverter 
defibrillators (ICD), cardiac resynchronisation therapy pacemakers (CRT-P), and the combined 
device, CRT-D, based on the presence of specific patient characteristics, recognising that the 
extent of clinical benefit associated with these devices varies across subgroups within the 
broader population of patients with HRrEF. 
Health care systems internationally are seeking evidence on the value for money of medical 
interventions, and ICD and CRT have been the subject of a number of economic evaluations4-9 
and health technology assessments (HTAs)10-12. In general, the conclusion has been that ICD 
and CRT are cost-effective when compared to medical therapy, and that CRT-D is marginally 
cost-effective when compared to standalone CRT-P.  
Clinical guidelines on ICD/CRT in HF make recommendations based on a range of clinical 
parameters. These include New York Heart Association (NYHA) class, Left Ventricular Ejection 
Fraction (LVEF), ischaemic aetiology status, QRS duration, and presence or absence of either 
Atrial Fibrillation (AF) or Left Bundle Branch Block (LBBB).2;3 Guidance issued by HTA 
organisations such as the National Institute for Health and Care Excellence (NICE)13;14 is based 
on a subset of these parameters. The great majority of published ICD/CRT economic 
evaluations, however, including those informing NICE decisions, have been based on data or 
populations from single clinical trials. These analyses do not, therefore, reflect the totality of 
randomised controlled trial evidence available, and have only limited information with which to 
explore the potential for cost-effectiveness (and decisions based on cost-effectiveness) to vary 
by patient sub-groups.  
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This paper reports a unique collaboration between manufacturers, clinicians and health 
economists to pool individual patient data from all major randomised controlled trials of these 
devices (N=12,638). This database of studies has been used to inform a range of research 
studies.15;16 We report its use to develop a cost-effectiveness analysis for submission to NICE 
as part of their comprehensive review of ICD and CRT designed to answer the question ‘in 
which patients are ICD/CRT-P/CRT-D cost-effective?’.16 Unlike previous studies, the analysis is 
based on a synthesis of evidence across trials and reflects important differences between sub-
groups, hence guiding health systems’ resource allocation decisions regarding these devices.  
Methods 
Decision analytic modelling  
The analysis is based on a typical UK HFrEF patient population, starting age of 66 years, all 
NYHA classes), and LVEF ≤35%. The cost-effectiveness analysis follows the methods 
recommended by NICE.17 Costs considered are those of the UK NHS, and outcomes are 
expressed as quality-adjusted life-years (QALYs). An annual discount rate of 3.5% is applied to 
both costs and benefits.17 
The analysis is based on a decision analytic model which comprises a series of regression 
equations to predict: mortality, hospitalisation rates and health related quality of life (HRQoL). 
The regression equations include covariables representing patients' baseline prognostic 
characteristics. The first regression equation predicts the probability of death in patients who 
only receive medical therapy. This is combined with estimates of the treatment effects of ICD, 
CRT-P and CRT-D based on the results of a network meta-analyses15 to derive device-specific 
mortality probabilities. A second equation is used to predict the monthly probability of 
experiencing a hospitalisation event for any reason. A final equation estimates a patient’s 
HRQoL given their characteristics and treatment. All living patients potentially incur other costs 
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related to device implant and replacement, background medication and routine clinical visits.  
Cost-effectiveness results are generated in a two-stage process. In the first stage, costs and 
QALYs are estimated for all interventions for all possible sets of patient characteristics (‘patient 
profiles’). In the second, these are collapsed to 24 subgroups defined by NYHA class, QRS 
duration and presence or absence of LBBB. Due to clinical contra-indications or a paucity of 
evidence, not all treatments are evaluated for each of the 24 sub-groups (see supplementary 
material, Appendix 1, for details).  
Expected (mean) costs a d QALYs are estimated for all relevant treatments in each sub-group, 
and the following standard ‘decision rules’ are followed to identify the cost-effective intervention 
in each sub-group.18 Firstly, any option that is less effective and more costly than one or more 
others is removed from consideration (dominated). Secondly, the extra cost per additional QALY 
(the incremental cost effectiveness ratio (ICER)) of a more effective treatment is calculated and 
any treatment that is less effective than another with a higher ICER is removed from 
consideration (extended dominance). The remaining options lie on a cost-effectiveness ‘frontier’ 
which runs from least to most costly/ effective. ICERs are calculated between each 
progressively more costly and effective option.  
Estimating model inputs 
The baseline mortality risk (patients receiving medical therapy alone) was estimated using 
relevant individual patient data from the included trials.15 Parametric survival analysis was used 
to extrapolate these mortality risks beyond the follow-up periods in the trials in order to generate 
lifetime estimates. The following candidate baseline covariables were selected based on data 
availability, a review of risk scores, clinical guidelines, RCT subgroup analyses and clinical 
advice: age, QRS duration, LVEF, gender, NYHA class, ischaemic aetiology, LBBB status and a 
binary geographic indicator to track whether or not patients were from a North American centre. 
Final covariable selection in all regression models was via a stepwise procedure unless 
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otherwise stated. Estimation of the treatment effects of the devices on all-cause mortality has 
been detailed elsewhere.15 Mortality treatment effects were assumed to be maintained for 7.5 
years (the maximum follow up period in the trials) after which they would decline so that, by 20 
years, there was no impact on mortality.  
The expected number of all-cause hospitalisations per month for patients on medical therapy, 
together with the treatment effects of the devices, was estimated from the 11 trials reporting 
relevant data (full list of studies reported in supplementary material, Appendix 2). 
Hospitalisation rates were assumed constant over a patient’s lifetime. Excluding LBBB 
morphology, the covariates of interest were as for all-cause mortality. NYHA I-II patients were 
considered together due to paucity of data on NYHA I patients. For the analysis of the effect of 
devices on hospitalisation rates, study specific intercepts were included as well as device 
related main effects with interaction terms used to identify treatment effect modifiers.  
HRQoL estimates expressed on a zero (equivalent of dead) to one (equivalent of good health) 
scale are necessary to quality-adjust survival and calculate QALYs.18 Baseline HRQoL 
conditional upon patients’ characteristics was estimated using data from the three trials 
reporting EQ-5D data (relevant studies listed in supplementary material, Appendix 2). The 
treatment effects of devices are estimated as the change from baseline (to first follow-up) in the 
treatment arms of the included trials, minus the change from baseline in patients allocated to 
medical therapy. This HRQoL treatment effect is assumed to be maintained for five years based 
on information in the CARE-HF trial,19 and then to decline to zero by ten years. Throughout the 
model, a decline in HRQoL is applied to reflect ageing, estimated using UK general population 
data.20 
Hospitalization costs are based on information on hospitalization type from a UK based 
population study.21 The typical HF medications for each NYHA class are estimated based on a 
review of the clinical literature and expert opinion. With the exception of those relating to device 
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systems, all costs are taken from national databases.22-24 The total implant cost for CRT-P is 
based on a relevant Healthcare Resource Group (HRG) code. For CRT-D and ICD, no such 
codes exist, so cross-manufacturer average selling prices for both systems and leads were 
made available by the Association of British Healthcare Industries (ABHI) for the purpose of this 
analysis (supplementary material, Appendix 3).  
Device longevity estimates are based on data from the Central Cardiac Audit Database (CCAD). 
Parametric survival models are used to model time to first and subsequent device replacements 
(supplementary material, Appendix 3). 
A range of sensitivity and scenario analyses are undertaken to quantify the importance of the 
key modelling assumptions. Of particular importance is the uncertainty in assumptions regarding 
the duration of the mortality and HRQoL treatment effects. Alternative values explored as 
sensitivity analyses were: i) a constant, lifetime mortality effect (as in previous UK 
reimbursement models10;12); ii) a five year time period; and iii) the mean follow up period from 
the studies included in the data analyses (2.54 years). A sensitivity analysis was also conducted 
using lifetime treatment effect durations for both all-cause mortality and HRQoL (as per previous 
UK reimbursement models). Further sensitivity analyses were undertaken including varying key 
costs, increasing device longevity, the use of an alternative approach to modelling all-cause 
hospitalisation and the use of NYHA class as a modifier of all-cause mortality treatment effect.  
Software 
All mortality related analyses were performed in R (www.r-project.org), with all analysis of 
hospitalisation and HRQoL performed in STATA V12 (StataCorp. College Station, TX: 
StataCorp LP). The economic model was developed in Microsoft Excel® (Microsoft Corporation, 
Redmond, WA). 
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Results 
All-cause mortality 
Full details of the mortality model are reported in the supplementary material (Appendix 4). 
The risk of death was higher in patients who are older, male or with ischaemic aetiology. The 
risk of death was also found to increase across NYHA classes, and was more than three times 
higher in individuals in NYHA class IV than those in NYHA I/II. The risk of mortality was lower in 
patients with a normal (<120ms) vs. longer QRS duration (hazard ratio = 0.84) and decreased 
as LVEF increased. Long term survival predictions for each subgroup and treatment are 
presented in the supplementary material (Appendix 5). Allowing for variations in within-group 
sample size and covariate mix the results are broadly internally consistent and in line with the 
published literature. 
All cause hospitalisation 
Full details of the baseline hospitalisation model are reported in the supplementary material 
(Appendix 4). Patients in NYHA classes III and IV were 2.1 and 4.4 times, respectively, more 
likely to be hospitalised than those in NYHA I/II. Ischaemic aetiology increased the rate of 
hospitalisation by 9% and wide QRS complex increased the rate by 22% (120-149ms) and 6% 
(150ms or more), respectively.  
The model predicted that ICDs reduced monthly hospitalisation rates by 20% in patients with 
NYHA I/II/III HF. CRT-P was associated with reductions in monthly hospitalisation rates of 32% 
and 40%, respectively, in patients with NYHA III/IV HF. CRT-D was associated with a monthly 
rate reduction of 30% in patients with NYHA I-IV HF. In NYHA III/IV patients the treatment 
effects arising from the patient level data for CRT-D compared to those generated for CRT-P 
were considered clinically implausible. For the base case analysis of these patients we therefore 
assumed equivalence of efficacy for CRT-D and CRT-P. Subgroup/ treatment specific lifetime 
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hospitalisation counts are reported in supplementary material (Appendix 5). These data 
require careful interpretation since subgroups with longer overall survival have more 
hospitalisation events. 
Health related quality of life 
Full details of the HRQoL model are reported in the supplementary material (Appendix 4). 
Statistically significant (p<0.05) but modest improvements from baseline were observed for ICD 
and CRT-D in patients with NYHA I or II heart failure, and CRT-P in NYHA Class III (+0.02, 
+0.03 and +0.091, respectively). No significant impact was observed on HRQoL with ICD or 
CRT-D therapy in patients in NYHA Class III. Meaningful results for patients with NYHA IV HF 
could not be generated due to the very low numbers of patients in the clinical trials. 
For the purposes of economic modelling, equivalence of HRQoL benefit for CRT-P and CRT-D 
was again assumed in NYHA III and IV HF. This assumption can be justified on the basis of a 
review of external sources and trial specific Minnesota Living with Heart Failure data.16 
Cost effectiveness – base case 
The base case results for all subgroups are presented in Table 1. For each patient sub-group, 
the order of treatments on the cost-effectiveness frontier is shown, and the ICERs for each 
option which is not subject to dominance or extended dominance. Table 2 shows the cost-
effective option for each sub-group (cost-effectiveness threshold: £30,000 per QALY gained). 
Device therapy is cost effective at this threshold in all sub-groups examined. CRT-D is cost 
effective in 10 of the 24 subgroups, and is cost effective for all LBBB morphology patients with 
NYHA I/II/III. ICDs are cost effective for all non-NYHA IV patients with a QRS duration <120ms 
and for NYHA I/II, non-LBBB morphology patients with a QRS duration between 120 and 
149ms. CRT-P is cost-effective for all NYHA IV patients evaluated. 
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Results generated using a more stringent threshold value (£20,000 per QALY gained) are 
presented in Table 3. CRT-D is only cost-effective in two patient groups (NYHA I or II, QRS 
duration ≥150ms, with LBBB); ICD is only cost-effective in two patient groups (NYHA I or II, 
QRS duration between 120 and 149ms, no LBBB); and CRT-P is cost-effective in six patient 
groups (NYHA III or IV, QRS duration >120ms, and LBBB and also NYHA III/IV, QRS duration 
≥150ms and no LBBB). 
The nature of the cost-effective intervention is dependent upon the cost effectiveness threshold 
(Figure 1). Beyond a threshold value of approximately £24,500 per QALY gained, for patients 
without LBBB morphology the treatments identified in the base case analysis are largely robust 
to changes in threshold. For patients with LBBB morphology there is generally less sensitivity to 
changes in threshold, with the cost-effective treatments presented in Table 2 largely unchanged 
beyond a threshold value of approximately £22,000 per QALY.  
Results in NYHA I and IV patients are subject to additional uncertainty due to the numbers of 
patients informing these analyses and the nature of the trial inclusion criteria for NYHA I 
patients, these issues are described in the discussion. 
Sensitivity analyses 
The choice of cost-effective therapy was, in general, unchanged when varying the duration of 
maximum all-cause mortality treatment effect (Table 4, threshold value £30,000 per QALY 
gained). A similar outcome was noted when the assumption of lifetime treatment effect 
durations for both all-cause mortality and HRQoL improvements was made (Table 4). A detailed 
breakdown of the fully incremental ICERs generated in this latter analysis is presented in the 
supplementary material (Appendix 6). The corresponding results generated using a threshold 
value of £20,000 per QALY gained are presented in Table 5. 
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The impact of varying key costs, increasing device longevity, the use of an alternative approach 
to modelling all-cause hospitalisation and the use of NYHA class as an all-cause mortality 
treatment effect modifier on the choice of devices at thresholds of £20,000 and £30,000 per 
QALY gained was modest. Hence, the model was robust to changes in these parameters.  
Discussion 
The clinical efficacy of CRT and ICD therapy has been investigated in numerous studies, and 
these technologies are established therapies for HFrEF individuals in international practice. The 
uniqueness of the database created for the purpose of this analysis lies in the ability to explore 
the clinical efficacy of CRT and ICD in detail, and in particular to pursue a thorough investigation 
of the impact of key clinical variables on both the baseline risk of death and the efficacy of each 
treatment option in reducing mortality.15 The database also facilitated the incorporation of 
clinical sub-groups into the cost-effectiveness assessment so the devices representing best 
value for money for patients with different sets of clinical characteristics could be identified. 
This collaboration can serve as a model for similar collaboration across manufacturers. Pooling 
together clinical data across manufactures can help manufactures, physicians, and policy 
makers become more confident in the clinical- and cost-effectiveness of a therapy and get a 
better understanding of how this varies across patients.  
The analysis presented here was used to inform the recent NICE guidance regarding the use of 
these technologies. The committee developing the NICE recommendations recognized this 
analysis as “a rich and important data source”25, and based its decision making on it. The 
guidance issued by NICE in 2014 reflected the findings of this cost-effectiveness analysis in 
almost all subgroups,25  with the exception of CRT-D in patients with NYHA III and QRS 120-
149ms without LBBB morphology and CRT-D in asymptomatic (NYHA Class I) patients with 
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QRS 120-149ms. ICD was recommended in both cases due to concerns about reduced 
effectiveness and a lack of symptomatic benefit of CRT in these subgroups.   
The major source of uncertainty identified during the NICE appraisal of these technologies was 
the duration of treatment effect on all-cause mortality. The duration of effect used in this 
analysis (7.5 years) is supported by a number of long-term studies. Recently published data 
from the CARE-HF study19 found that, at a mean follow-up of 56 months in the CRT-P and 50 
months in the medical therapy arms, the hazard ratio for all cause-mortality (CRT-P vs. OPT) 
was 0.77 [95% CI 0.63, 0.93], despite 39% of control patients crossing-over to a CRT device 
during follow-up. In addition, long-term follow-up from the MADIT-II study26 found that, at a 
median follow-up of 7.6 years, the hazard ratio for all cause-mortality (ICD vs. non-ICD) was 
0.77 [0.65, 0.91], although 34% of control patients crossed-over to a device during follow-up. 
Attempts to adjust statistically for cross-over resulted in treatment effect estimates of 0.67 [0.56, 
0.80] and 0.66 [0.56, 0.78], in CARE-HF and MADIT-II, respectively.19,26  
The results from our analysis, generated using a cost-effectiveness threshold of £30,000 per 
QALY gained broadly agrees with guidelines issued by the European Society of Cardiology.3,27 
In patients with QRS<120ms, NYHA II-III and EF≤35%, ICD is recommended and cost-effective 
according to our analysis. In ambulatory NYHA IV patients with prolonged QRS duration, CRT-P 
is recommended and cost-effective. Our analysis provides information on where scarce 
resources should be targeted in patients with QRS prolongation and in NYHA class II or III 
where several possible device options are recommended. In particular, it suggests that CRT-D 
is cost-effective in NYHA II-III patients with LBBB morphology, and that, in patients with non-
LBBB morphology, CRT-D is cost-effective in all groups with the exception of NYHA II patients 
with a QRS duration of 120-149ms. Unlike previous guidelines, the current analysis suggests 
implantable devices may be cost-effective in asymptomatic patients (NYHA Class I).  However, 
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given the small number of patients in these groups in the trials, results in NYHA Class I, and in 
particular in relation to CRT-D in this patient group, should be regarded with caution.15 
Comparison of the results from the current analysis with previous UK HTA models of ICD and 
CRT is challenging due to the different model structures and evidence used. The earlier models 
used aggregate level evidence, whereas the current model was based on access to a large 
amount of individual patient data. Accepting these differences, the results from the sensitivity 
analysis performed with the removal of all tapering effects on treatment effect durations are the 
most comparable with earlier models. This showed that the ICERs from the current analysis are 
lower (i.e. better value for money) than those considered acceptable in previous NICE guidance. 
The reasons for this are likely to be increases in average device longevity and a reduction in 
hardware acquisition costs. In many cases, where ICD was historically recommended, the 
current analysis suggests patients should be offered a CRT-D device as the most clinically and 
cost-effective option. 
A number of limitations arose from the choice of modeling approach and data on which the 
analyses were based, with the main area of potential concern being that some of the patient 
groups modeled were sparsely represented in our database. The primary groups of concern 
relate to patients in NYHA Class I and IV HF (regardless of LBBB status). Cost-effectiveness 
results in these groups may have been influenced by the small patient numbers and should be 
treated with caution. In addition, NYHA I patients in trials may be atypical of those observed in 
clinical practice as specific inclusion criteria were used to focus on patients who were easily 
identifiable.28,29  
Omitting previous HF hospitalisations as a predictor of subsequent monthly hospitalisation 
events represents a limitation of our analysis. However, the total event rates predicted are low 
and the choice of modelling approach is therefore unlikely to have had a substantive impact on 
the model results.  
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In conclusion, from a UK NHS perspective, at a threshold of £30,000 per QALY gained our 
analysis has shown that CRT-D is cost effective in a far wider group of patients than previously 
recommended and that, for most other patients, ICD is a cost-effective treatment alternative. 
Our analysis also showed that CRT-P was cost-effective in all patients with NYHA III/IV and a 
QRS duration >120ms. Device therapy is cost-effective in most patient groups with LBBB at a 
threshold of £20,000 per QALY gained. 
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Figure legends 
Figure 1: Graphic display of cost-effective option across cost-effectiveness threshold values (base case) 
.
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Text tables 
Table 1: Base case results. Cost-effectiveness sequence relates to the order in which interventions appear on the cost-effectiveness frontier. “N/A” represents 
fewer than four interventions being considered. Options labelled as “Dominated“ or “Ext Dominated” do not lie on the frontier  
 Cost-effectiveness sequence Incremental cost-effective ratios 
Patient group 1st 2
nd
 3
rd
 4
th
 1
st
 2nd 3
rd
 4th 
Individuals without LBBB morphology 
NYHA I, QRS duration <120ms
a
 MT ICD N/A N/A Referent £24,074 N/A N/A 
NYHA I, QRS duration≥120ms and <150ms
a
 MT CRT-D ICD N/A Referent Dominated £16,253 N/A 
NYHA I, QRS duration≥150ms
a
 MT ICD CRT-D N/A Referent £21,102 £21,759 N/A 
NYHA II, QRS duration<120ms MT ICD N/A N/A Referent £24,465 N/A N/A 
NYHA II, QRS duration≥120ms and <150ms MT CRT-D ICD N/A Referent Dominated £16,813 N/A 
NYHA II, QRS duration≥150ms MT ICD CRT-D N/A Referent £20,602 £23,738 N/A 
NYHA III, QRS duration<120ms MT ICD N/A N/A Referent £27,826 N/A N/A 
NYHA III, QRS duration≥120ms and <150ms MT CRT-P ICD CRT-D Referent £20,178 Ext Dominated £23,349 
NYHA III, QRS duration≥150ms MT ICD CRT-P CRT-D Referent Dominated £13,930 £25,200 
NYHA IV, QRS duration<120ms MT N/A N/A N/A Referent N/A N/A N/A 
NYHA IV, QRS duration≥120ms and <150ms MT CRT-P CRT-D N/A Referent £22,578 £40,052 N/A 
NYHA IV, QRS duration≥150ms MT CRT-P CRT-D N/A Referent £17,175 £35,811 N/A 
Individuals with LBBB morphology 
NYHA I, QRS duration≥120ms and <150ms
a
 MT ICD CRT-D N/A Referent £20,677 £21,672 N/A 
NYHA I, QRS duration≥150ms
a
 MT ICD CRT-D N/A Referent Ext Dominated £17,470 N/A 
NYHA II, QRS duration≥120ms and <150ms MT ICD CRT-D N/A Referent Ext Dominated £20,704 N/A 
NYHA II, QRS duration≥150ms MT ICD CRT-D N/A Referent Ext Dominated £17,664 N/A 
NYHA III, QRS duration≥120ms and <150ms MT ICD CRT-P CRT-D Referent Dominated £14,215 £24,875 
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NYHA III, QRS duration≥150ms MT ICD CRT-P CRT-D Referent Dominated £10,496 £28,646 
NYHA IV, QRS duration≥120ms and <150ms MT CRT-P CRT-D N/A Referent £18,664 £37,104 N/A 
NYHA IV, QRS duration≥150ms MT CRT-P CRT-D N/A Referent £14,500 £40,449 N/A 
MT: Medical therapy; ICD: Implantable cardioverter-defibrillator; CRTP: standalone CRT device; CRTD: combined CRT and ICD device; N/A: Not applicable; a) 
Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For 
further detail see main text.  
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Table 2: Summary of cost-effectiveness recommendations arising from the base case analysis 
(threshold value: £30,000 per QALY gained) 
NYHA QRS duration<120ms QRS duration 120-150ms QRS duration>150ms 
Patients without LBBB morphology 
I
a
 ICD  ICD CRT-D 
II ICD  ICD CRT-D 
III ICD  CRT-P / CRT-D
b
 CRT-P / CRT-D
b
 
IV Medical therapy  CRT-P  CRT-P  
Patients with LBBB morphology 
I
a
  CRT-D CRT-D 
II  CRT-D CRT-D 
III  CRT-P / CRT-D
b
 CRT-P / CRT-D
b
 
IV  CRT-P  CRT-P 
a) Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due 
to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text. b) Instances where 
NICE recommended two devices based on fully incremental results and a threshold of £30,000 per QALY gained. 
CRT-P values are relative to medical therapy and CRT-D values relative to CRT-P. 
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Table 3: Summary of cost-effectiveness recommendations arising from the base case analysis 
(threshold value: £20,000 per QALY gained) 
NYHA QRS duration<120ms QRS duration 120-150ms QRS duration>150ms 
Patients without LBBB morphology 
I
a
 Medical Therapy ICD Medical Therapy 
I Medical Therapy ICD Medical Therapy 
III Medical Therapy Medical Therapy CRT-P 
IV Medical Therapy Medical Therapy CRT-P  
Patients with LBBB morphology 
I
a
  Medical Therapy CRT-D 
II  Medical Therapy CRT-D 
III  CRT-P CRT-P 
IV  CRT-P  CRT-P 
a) Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due 
to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text.  
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Table 4: Impact of duration of treatment effect on treatment choice (threshold £30,000 per QALY 
gained). Changes from base case highlighted in bold 
 Duration of mortality treatment effect Lifetime 
mortality and 
constant 
HRQoL 
Subgroup Lifetime 7.5 years 5 years Mean f/up 
Individuals without LBBB 
NYHA I, QRS <120ms
a
 ICD ICD ICD ICD ICD 
NYHA I, QRS ≥120ms and <150ms
a
 ICD ICD ICD ICD ICD 
NYHA I, QRS ≥150ms
a
 CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA II, QRS <120ms ICD ICD ICD ICD ICD 
NYHA II, QRS ≥120ms and <150ms ICD ICD ICD ICD ICD 
NYHA II, QRS ≥150ms CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA III, QRS <120ms ICD ICD ICD MT ICD 
NYHA III, QRS ≥120ms and <150ms CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA III, QRS ≥150ms CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA IV, QRS <120ms MT MT MT MT MT 
NYHA IV, QRS ≥120ms and <150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
NYHA IV, QRS ≥150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
Individuals with LBBB 
NYHA I, QRS ≥120ms and <150ms
a
 CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA I, QRS ≥150ms
a
 CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA II, QRS ≥120ms and <150ms CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA II, QRS ≥150ms CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA III, QRS ≥120ms and <150ms CRT-D CRT-D CRT-D CRT-D CRT-D 
NYHA III, QRS ≥150ms CRT-D CRT-D CRT-P CRT-P CRT-D 
NYHA IV, QRS ≥120ms and <150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
NYHA IV, QRS ≥150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
MT: Medical Therapy; a) Results in NYHA I and IV patients are based on relatively low patient numbers and may 
be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text.  
  
Page 26 of 46
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
26 
 
Table 5: Impact of duration of treatment effect on treatment choice (threshold £20,000 per QALY 
gained). Changes from base case highlighted in bold 
 Duration of mortality treatment effect Lifetime 
mortality and 
constant 
HRQoL 
Subgroup Lifetime 7.5 years 5 years Mean f/up 
Individuals without LBBB 
NYHA I, QRS <120ms
a
 ICD MT MT MT ICD 
NYHA I, QRS ≥120ms and <150ms
a
 ICD ICD ICD ICD ICD 
NYHA I, QRS ≥150ms
a
 CRT-D MT MT MT CRT-D 
NYHA II, QRS <120ms ICD MT MT MT ICD 
NYHA II, QRS ≥120ms and <150ms ICD ICD ICD ICD ICD 
NYHA II, QRS ≥150ms CRT-D MT MT MT ICD 
NYHA III, QRS <120ms MT MT MT MT MT 
NYHA III, QRS ≥120ms and <150ms CRT-P MT MT MT CRT-P 
NYHA III, QRS ≥150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
NYHA IV, QRS <120ms MT MT MT MT MT 
NYHA IV, QRS ≥120ms and <150ms MT MT MT MT MT 
NYHA IV, QRS ≥150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
Individuals with LBBB 
NYHA I, QRS ≥120ms and <150ms
a
 CRT-D MT MT MT CRT-D 
NYHA I, QRS ≥150ms
a
 CRT-D CRT-D CRT-D MT CRT-D 
NYHA II, QRS ≥120ms and <150ms CRT-D MT MT MT CRT-D 
NYHA II, QRS ≥150ms CRT-D CRT-D CRT-D MT CRT-D 
NYHA III, QRS ≥120ms and <150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
NYHA III, QRS ≥150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
NYHA IV, QRS ≥120ms and <150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
NYHA IV, QRS ≥150ms CRT-P CRT-P CRT-P CRT-P CRT-P 
a) Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due 
to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text.  
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Figure 1: Graphic display of cost-effective option across cost-effectiveness threshold values (base case)  
297x420mm (300 x 300 DPI)  
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SUPPLEMENTARY ONLINE MATERIAL 
Appendix 1: Rational for excluding interventions from some 
subgroups 
 
Table S1: Rationale for excluding interventions from some subgroups 
Treatment option Subgroup from 
which excluded 
Rationale/ justification 
Medical Therapy None   
ICD NYHA IV Minimal IPD data available from clinical trials (of 12,638 patients 
included in IPD database only 77 (0.6%) were NYHA IV and 
randomised to an ICD)  
CRT-P NYHA I/II 
 
Minimal IPD data available from clinical trials (of 12,638 patients 
included in IPD database only 74 (0.6%) were NYHA I-II and 
randomised to a CRT-P) 
QRS duration<120ms Prolonged QRS duration required for consideration of device 
insertion. No evidence of benefit from CRT in patients with 
normal QRS duration 
CRT-D QRS duration<120ms Prolonged QRS duration required for consideration of device 
insertion. No evidence of benefit from CRT in patients with 
normal QRS duration 
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Appendix 2: List of studies contributing information to all-cause 
hospitalisation and health related quality of life analyses 
All-cause hospitalisation 
Abraham WT, Fisher WG, Smith AL, DeLurgio DB, Leon AR, Loh E et al. Cardiac 
resynchronization in chronic heart failure. New England Journal of Medicine 2002; 
346(24):1845-1853. 
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an 
implantable cardioverter-defibrillator for congestive heart failure.[Erratum appears in N Engl 
J Med. 2005 May 19;352(20):2146]. New England Journal of Medicine 2005; 352(3):225-
237. 
Beshai JF, Grimm RA, Nagueh SF, Baker JH, Beau SL, Greenberg SM et al. Cardiac-
resynchronization therapy in heart failure with narrow QRS complexes. New England Journal 
of Medicine 2007; 357(24):2461-2471. 
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De MT et al. Cardiac-
resynchronization therapy with or without an implantable defibrillator in advanced chronic 
heart failure. New England Journal of Medicine 2004; 350(21):2140-2150. 
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. The 
effect of cardiac resynchronization on morbidity and mortality in heart failure. New England 
Journal of Medicine 2005; 352(15):1539-1549. 
Higgins SL, Hummel JD, Niazi IK, Giudici MC, Worley SJ, Saxon LA et al. Cardiac 
Resynchronization Therapy for the Treatment of Heart Failure in Patients with 
Intraventricular Conduction Delay and Malignant Ventricular Tachyarrhythmias. Journal of 
the American College of Cardiology 2003; 42(8):1454-1459. 
Linde C, Abraham WT, Gold MR, St John SM, Ghio S, Daubert C et al. Randomized trial of 
cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic 
patients with left ventricular dysfunction and previous heart failure symptoms. Journal of the 
American College of Cardiology 2008; 52(23):1834-1843. 
Moss A. MADIT-CRT: The multicentre automatic defibrillator implantation trial-cardiac 
resynchronization therapy. European Journal of Heart Failure 2009; 11(12):1217-1219. 
RHYTHM ICD. St. Jude Medical® Epic™ HF System including the Epic™ HF Model V-338 
Cardiac Resynchronization Therapy Defibrillator, the Aescula™ LV Model 1055K Lead, the 
QuickSite™ LV Model 1056K Lead, and the Model 3307 v4.5m Programmer Software - 
P030054. US Food and Drug Administration  
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Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al. Cardiac-
resynchronization therapy for mild-to-moderate heart failure. New England Journal of 
Medicine 2010; 363(25):2385-2395. 
Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B et al. Combined 
cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic 
heart failure: the MIRACLE ICD Trial. JAMA : the journal of the American Medical 
Associatio  2003; 289:2685-2694. 
Health Related Quality of Life 
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. The 
effect of cardiac resynchronization on morbidity and mortality in heart failure. New England 
Journal of Medicine 2005; 352(15):1539-1549. 
Moss A. MADIT-CRT: The multicentre automatic defibrillator implantation trial-cardiac 
resynchronization therapy. European Journal of Heart Failure 2009; 11(12):1217-1219. 
Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al. Cardiac-
resynchronization therapy for mild-to-moderate heart failure. New England Journal of 
Medicine 2010; 363(25):2385-2395. 
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Appendix 3: Additional model parameters 
 
Table S2: Background medication by NYHA class (% patients receiving each drug) 
 NYHA I NYHA II NYHA III NYHA IV 
Atorvastatin 20% 20% 20% 20% 
Simvastatin 55% 55% 55% 55% 
Warfarin 10% 15% 25% 40% 
Clopidogrel 15% 15% 15% 15% 
Ramipril 90% 90% 90% 90% 
Carvedilol 85% 85% 75% 70% 
Spironolactone 0% 30% 30% 30% 
Digoxin 5% 25% 25% 25% 
Furosemide 75% 80% 90% 95% 
Eplerenone 0% 30% 30% 30% 
 
  
Page 32 of 46
https://mc.manuscriptcentral.com/heart
Heart
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
5 
 
Table S3: Medication purchase costs (all data taken from the British National Formulary
24
, cost year 
2012) 
Drug Tablets per pact Daily dose Pack price 
Atrovastatin (Liptor®) 28 10mg £13.00 
Simvastatin 28 10mg £0.90 
 28 20mg £1.01 
 28 40mg £1.32 
 28 80mg £2.29 
Warfarin 28 0.5mg £1.49 
 28 1mg £0.93 
Clopidigrel 30 75mg £3.40 
 28 75mg £3.17 
Ramipril 28 1.25mg £1.10 
 28 2.5mg £1.18 
 28 5mg £1.25 
 28 10mg £1.41 
Carvedilol 28 3.125mg £1.10 
 28 6.25mg £1.25 
 28 12.5mg £1.37 
 28 25mg £1.84 
Spironolactone 28 25mg £1.55 
 28 50mg £2.11 
 28 100mg £2.46 
Digoxin 28 62.5 £2.03 
 28 125 £1.12 
 28 250 £1.13 
Furosemide 28 20 £0.81 
 28 40 £0.84 
 28 500 £4.05 
Eplerenone 28 25 £42.72 
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Table S4: Hospitalisation event costs (cost year 2012) 
Item Cost Source 
Day in hospital (HF) £655.71 NHS Schedule of reference costs
16,22
 
Day in hospital (non-HF) £699.50 NHS Schedule of reference costs
16,22
 
Day in hospital (leads) £794.41 NHS Schedule of reference costs
16,22
 
HF hospitalisation event £2,295 NHS Schedule of reference costs
16,22
 
Non-HF hospitalisation event £2,448 NHS Schedule of reference costs
16,22
 
Outpatient visits
a
 £110.00 Unit costs of health and social care
16,23
 
a) Applied every six months to all patients alive regardless of device option in addition to any other hospitalisation 
event costs.  
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Table S5: ICD and CRT system costs (source Association of British Healthcare Industries unless 
otherwise stated, cost year 2012) 
Item Cost Source 
System costs 
CRT-P whole system costs (device and leads) £3,411 Association of British Healthcare Industries* 
CRT-D whole system costs (device and leads) £12,293 Association of British Healthcare Industries* 
ICD whole system costs (device and leads) £9,692 Association of British Healthcare Industries* 
CRT Leads £510 Association of British Healthcare Industries* 
CRT-P pulse generator £2,600 Association of British Healthcare Industries* 
CRT-D pulse generator £11,752 Association of British Healthcare Industries* 
ICD generator £9,149 Association of British Healthcare Industries* 
UK Tariff values 
CRT-P £8,281 NHS Schedule of reference costs
16,22
 
ICD/CRT-D non-purchase costs £5,556 NHS Schedule of reference costs
16,22
 
Revisions not requiring new device £2,748 NHS Schedule of reference costs
16,22
 
* Data on file 
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Table S6: Device costs used in the model (cost year 2012) 
Item Cost Components 
Initial implant operation (ICD) £15,248 ABHI system costs (incl. leads) and UK tariff EA12Z 
Initial implant operation (CRT-P) £8,281 UK Tariff E07Z 
Initial implant operation (CRT-D) £17,849 ABHI system costs (incl. leads) and UK tariff EA12Z 
Replacement (ICD) £14,705 ABHI system costs (excl. leads) and UK tariff EA12Z 
Replacement (CRT-P) £8,281 UK Tariff E07Z 
Replacement (CRT-D) £17,308 ABHI System costs (excl. leads)* and UK tariff EA12Z 
Device related infection (ICD) £18,964 See footnote 
Device related infection (CRT-P) £12,541 See footnote 
Device related infection (CRT-D) £21,568 See footnote 
Battery replacement (ICD) £12,004 ABHI generator costs (excl. leads) and UK tariff EA39Z 
Battery replacement (CRT-P) £8,381 UK Tariff EA07Z
 
Battery replacement (CRT-D) £14,672 ABHI generator costs (excl. leads) and UK tariff EA39Z 
As per previous NICE appraisal of CRT, for the purpose of costing we have assumed that treatment of a device 
related infection involves explanation of the existing device and a de novo device reimplantation as well as an 
additional outpatient visit. Detailed breakdown of the relevant resource use protocol can be found in the ABHI 
NICE submission dossier.
16
 
Table S7: Parameter estimates which to inform Weibull models (time to first device failure)
a
 
Parameter ICD CRT-P CRT-D 
Log-Lambda -15.784 -14.287 -15.465 
Gamma 1.943 1.689 1.935 
a) Full details on source data and the modelling of device longevity to be found in the relevant NICE 
submission25 
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Appendix 4: Clinical baseline risk equations 
Table S8: Preferred baseline risk models (all-cause mortality and hospitalisation) 
 All-cause mortality (Weibull model)  All-cause hospitalisation (negative binomial model) 
Variable Coefficient Hazard ratio
a
 P-value  Coefficient Hazard ratio
b
 P-value 
Age (per year), time-dependent covariate 0.03 1.02 <0.001  0.02 1.00 0.004 
Male gender 0.24 1.24 0.003  N/A N/A N/A 
NYHA III 0.62 1.74 <0.001  0.74 2.10 <0.001 
NYHA IV 1.30 3.20 <0.001  1.48 4.41 <0.001 
Ischaemic aetiology 0.37 1.39 <0.001  0.09 1.09 0.031 
QRS duration <120ms -0.20 0.84 0.002  N/A N/A N/A 
QRS duration ≥120ms  and <150ms N/A N/A N/A  0.20 1.22 <0.001 
QRS duration ≥150ms N/A N/A N/A  0.06 1.06 <0.001 
LVEF>20% and <=25% -0.26 0.79 0.001  N/A N/A N/A 
LVEF>25% and <=30% -0.34 0.74 <0.001  N/A N/A N/A 
LVEF>30% -0.65 0.56 <0.001  N/A N/A N/A 
log(scale) 10.09 N/A <0.001  N/A N/A N/A 
log(shape) 0.12 N/A <0.001  N/A N/A N/A 
Constant N/A N/A N/A  -2.73 N/A N/A 
a) Hazard ratio = exp(coefficient/shape); b) hazard ratio = exp(coefficient). N/A = not applicable 
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Table S9: Negative Binomial Regression coefficients used to predict baseline utility 
Covariable Coefficient Hazard ratio
a
 p-value 
NYHA = III 0.4667 1.595 <0.001 
NYHA = IV* 0.7721 2.164 0.117 
Age -0.0061 0.994 0.003 
Ischaemic aetiology 0.1427 1.153 0.001 
Gender= Male -0.2296 0.794 <0.001 
Constant 3.5271 N/A N/A 
a) Hazard ratio =exp(coefficient);  
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Appendix 5: Long term survival extrapolation and lifetime hospitalisation counts 
Table S10: Predicted overall survival and lifetime hospitalisation event estimates (Medical Therapy, where included as a treatment option) 
 Predicted overall survival 
Hospitalisation count (lifetime) Pt. group 0 yrs 2 yrs 4 yrs 6 yrs 8 yrs 10 yrs Median 
Individuals without LBBB morphology 
NYHA I, QRS duration<120ms
a
 100.0% 87.5% 74.5% 62.0% 51.3% 42.0% 8.96 1.58 
NYHA I, QRS duration≥120ms and <150ms
a
 100.0% 82.0% 64.6% 49.3% 37.5% 28.0% 6.37 1.44 
NYHA I, QRS duration≥150ms
a
 100.0% 80.8% 62.7% 46.9% 35.0% 25.7% 6.06 1.19 
NYHA II, QRS duration<120ms 100.0% 89.3% 77.9% 66.8% 57.0% 48.3% 10.61 1.78 
NYHA II, QRS duration≥120ms and <150ms 100.0% 83.4% 67.1% 52.5% 40.8% 31.4% 7.00 1.54 
NYHA II, QRS duration≥150ms 100.0% 82.4% 65.4% 50.4% 38.7% 29.4% 6.66 1.28 
NYHA III, QRS duration<120ms 100.0% 78.3% 59.0% 43.2% 31.9% 23.4% 5.78 2.14 
NYHA III, QRS duration≥120ms and <150ms 100.0% 69.8% 46.3% 29.7% 19.3% 12.6% 4.08 1.91 
NYHA III, QRS duration≥150ms 100.0% 66.3% 41.5% 25.0% 15.4% 9.5% 3.58 1.49 
NYHA IV, QRS duration<120ms 100.0% 52.0% 25.3% 11.7% 5.5% 2.6% 2.32 1.94 
NYHA IV, QRS duration≥120ms and <150ms 100.0% 45.5% 19.9% 8.7% 4.1% 2.0% 2.02 2.03 
NYHA IV, QRS duration≥150ms 100.0% 42.6% 17.0% 6.5% 2.6% 1.0% 1.82 1.59 
Individuals with LBBB morphology 
NYHA I, QRS duration≥120ms and <150ms
a
 100.0% 83.4% 67.2% 52.7% 41.2% 31.9% 7.23 1.58 
NYHA I, QRS duration≥150ms
a
 100.0% 82.1% 64.8% 49.6% 37.8% 28.5% 6.56 1.27 
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NYHA II, QRS duration≥120ms and <150ms 100.0% 84.8% 69.7% 55.9% 44.8% 35.5% 7.82 1.66 
NYHA II, QRS duration≥150ms 100.0% 85.0% 70.2% 56.5% 45.4% 36.2% 7.90 1.45 
NYHA III, QRS duration≥120ms and <150ms 100.0% 69.8% 46.6% 30.3% 20.1% 13.5% 4.19 1.94 
NYHA III, QRS duration≥150ms 100.0% 70.3% 47.2% 30.8% 20.4% 13.6% 4.20 1.68 
NYHA IV, QRS duration≥120ms and <150ms 100.0% 46.8% 21.1% 9.7% 5.0% 2.7% 2.16 2.10 
NYHA IV, QRS duration≥150ms 100.0% 45.6% 20.1% 8.8% 4.2% 2.0% 2.03 1.73 
a) Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For 
further detail see main text.  
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Table S11: Predicted overall survival and lifetime hospitalisation event estimates (ICD, where included as a treatment option) 
 Predicted overall survival 
Hospitalisation count (lifetime) Pt. group 0 yrs 2 yrs 4 yrs 6 yrs 8 yrs 10 yrs Median 
Individuals without LBBB morphology 
NYHA I, QRS duration<120ms
a
 100.0% 90.5% 80.2% 69.9% 60.6% 51.8% 11.08 1.47 
NYHA I, QRS duration≥120ms and <150ms
a
 100.0% 88.3% 76.1% 64.1% 53.8% 44.1% 9.25 1.52 
NYHA I, QRS duration≥150ms
a
 100.0% 86.1% 71.9% 58.5% 47.4% 37.5% 8.06 1.19 
NYHA II, QRS duration<120ms 100.0% 91.9% 83.0% 73.9% 65.6% 57.6% 12.83 1.63 
NYHA II, QRS duration≥120ms and <150ms 100.0% 89.2% 77.7% 66.4% 56.5% 47.0% 9.90 1.59 
NYHA II, QRS duration≥150ms 100.0% 87.4% 74.3% 61.8% 51.2% 41.6% 8.86 1.27 
NYHA III, QRS duration<120ms 100.0% 83.1% 66.9% 52.7% 41.6% 32.4% 7.32 2.05 
NYHA III, QRS duration≥120ms and <150ms 100.0% 79.4% 60.7% 45.2% 33.7% 24.5% 6.00 2.10 
NYHA III, QRS duration≥150ms 100.0% 74.8% 53.4% 37.0% 25.8% 17.6% 4.89 1.55 
Individuals with LBBB morphology 
NYHA I, QRS duration≥120ms and <150ms
a
 100.0% 88.2% 75.8% 63.8% 53.5% 44.1% 9.48 1.55 
NYHA I, QRS duration≥150ms
a
 100.0% 86.0% 71.7% 58.3% 47.2% 37.5% 8.12 1.20 
NYHA II, QRS duration≥120ms and <150ms 100.0% 89.0% 77.4% 66.0% 56.1% 46.9% 10.05 1.60 
NYHA II, QRS duration≥150ms 100.0% 88.2% 75.9% 64.0% 53.9% 44.7% 9.60 1.33 
NYHA III, QRS duration≥120ms and <150ms 100.0% 77.3% 57.5% 41.7% 30.5% 22.0% 5.61 1.98 
NYHA III, QRS duration≥150ms 100.0% 75.3% 54.4% 38.3% 27.2% 19.1% 5.11 1.58 
a) Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For 
further detail see main text.  
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Table S12: Predicted overall survival and lifetime hospitalisation event estimates (CRT-P, where included as a treatment option) 
 Predicted overall survival 
Hospitalisation count (lifetime) Pt. group 0 yrs 2 yrs 4 yrs 6 yrs 8 yrs 10 yrs Median 
Individuals without LBBB morphology 
NYHA III, QRS duration≥120ms and <150ms 100.0% 71.4% 48.4% 31.7% 21.0% 13.9% 4.29 1.35 
NYHA III, QRS duration≥150ms 100.0% 71.9% 49.0% 32.1% 21.2% 13.8% 4.31 1.19 
NYHA IV, QRS duration≥120ms and <150ms 100.0% 48.5% 22.7% 10.7% 5.4% 2.8% 2.21 1.33 
NYHA IV, QRS duration≥150ms 100.0% 50.9% 24.2% 11.1% 5.3% 2.4% 2.27 1.18 
Individuals with LBBB morphology 
NYHA III, QRS duration≥120ms and <150ms 100.0% 74.9% 53.8% 37.7% 26.7% 18.7% 5.05 1.54 
NYHA III, QRS duration≥150ms 100.0% 78.7% 59.6% 44.0% 32.6% 23.6% 5.82 1.50 
NYHA IV, QRS duration≥120ms and <150ms 100.0% 54.8% 28.6% 14.8% 8.1% 4.6% 2.67 1.54 
NYHA IV, QRS duration≥150ms 100.0% 58.7% 32.8% 17.9% 10.1% 5.6% 2.90 1.45 
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Table S13: Predicted overall survival and lifetime hospitalisation event estimates (CRT-D, where included as a treatment option) 
 Predicted overall survival 
Hospitalisation count (lifetime) Pt. group 0 yrs 2 yrs 4 yrs 6 yrs 8 yrs 10 yrs Median 
Individuals without LBBB morphology 
NYHA I, QRS duration≥120ms and <150ms
a
 100.0% 87.0% 73.5% 60.6% 49.6% 39.7% 8.37 1.24 
NYHA I, QRS duration≥150ms
a
 100.0% 87.7% 74.8% 62.2% 51.5% 41.5% 8.71 1.10 
NYHA II, QRS duration≥120ms and <150ms 100.0% 88.1% 75.6% 63.4% 52.9% 43.3% 9.15 1.31 
NYHA II, QRS duration≥150ms 100.0% 88.7% 76.8% 65.1% 54.8% 45.1% 9.48 1.16 
NYHA III, QRS duration≥120ms and <150ms 100.0% 77.8% 58.0% 42.0% 30.5% 21.6% 5.52 1.72 
NYHA III, QRS duration≥150ms 100.0% 77.5% 57.5% 41.2% 29.6% 20.6% 5.36 1.46 
NYHA IV, QRS duration≥120ms and <150ms 100.0% 57.7% 31.7% 17.3% 9.8% 5.5% 2.86 1.95 
NYHA IV, QRS duration≥150ms 100.0% 58.9% 32.5% 17.2% 9.3% 4.7% 2.81 1.68 
Individuals with LBBB morphology 
NYHA I, QRS duration≥120ms and <150ms
a
 100.0% 89.5% 78.2% 67.1% 57.3% 47.9% 10.18 1.42 
NYHA I, QRS duration≥150ms
a
 100.0% 89.9% 79.0% 68.0% 58.3% 48.6% 10.18 1.23 
NYHA II, QRS duration≥120ms and <150ms 100.0% 90.5% 80.2% 69.9% 60.7% 51.6% 10.99 1.49 
NYHA II, QRS duration≥150ms 100.0% 91.6% 82.5% 73.1% 64.6% 55.8% 11.85 1.35 
NYHA III, QRS duration≥120ms and <150ms 100.0% 80.3% 62.2% 47.0% 35.7% 26.4% 6.32 1.90 
NYHA III, QRS duration≥150ms 100.0% 82.8% 66.4% 51.9% 40.6% 30.8% 7.02 1.77 
NYHA IV, QRS duration≥120ms and <150ms 100.0% 62.9% 37.6% 22.0% 13.3% 8.0% 3.37 2.21 
NYHA IV, QRS duration≥150ms 100.0% 65.4% 40.8% 24.8% 15.4% 9.1% 3.56 2.02 
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a) Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For 
further detail see main text.  
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Appendix 6: Results from additional economic sensitivity analyses 
Table S14: Cost-effectiveness results generated using constant treatment effects 
 C-E Sequence ICERs 
Pt. group 1st 2nd 3
rd
 4th 1
st
 2nd 3
rd
 4
th
 
Individuals without LBBB morphology 
NYHA I, QRS duration<120ms
a
 MT ICD N/A N/A Referent £17,799 N/A N/A 
NYHA I, QRS duration≥120ms and <150ms
a
 MT CRTD ICD N/A Referent Dominated £12,991 N/A 
NYHA I, QRS duration≥150ms
a
 MT ICD CRTD N/A Referent £17,390 £19,372 N/A 
NYHA II, QRS duration<120ms MT ICD N/A N/A Referent £17,305 N/A N/A 
NYHA II, QRS duration≥120ms and <150ms MT CRTD ICD N/A Referent Dominated £13,210 N/A 
NYHA II, QRS duration≥150ms MT ICD CRTD N/A Referent £16,577 £20,796 N/A 
NYHA III, QRS duration<120ms MT ICD N/A N/A Referent £24,187 N/A N/A 
NYHA III, QRS duration≥120ms and <150ms MT CRTP ICD CRTD eferent £17,350 Ext Dominated £20,117 
NYHA III, QRS duration≥150ms MT ICD CRTP CRTD Referent Dominated £12,008 £20,692 
NYHA IV, QRS duration<120ms MT N/A N/A N/A Referent N/A N/A N/A 
NYHA IV, QRS duration≥120ms and <150ms MT CRTP CRTD N/A Referent £21,805 £37,981 N/A 
NYHA IV, QRS duration≥150ms MT CRTP CRTD N/A Referent £16,271 £33,035 N/A 
Individuals with LBBB morphology 
NYHA I, QRS duration≥120ms and <150ms
a
 MT ICD CRTD N/A Referent £16,438 £18,239 N/A 
NYHA I, QRS duration≥150ms
a
 MT ICD CRTD N/A Referent Ext Dominated £14,058 N/A 
NYHA II, QRS duration≥120ms and <150ms MT ICD CRTD N/A Referent Ext Dominated £16,318 N/A 
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NYHA II, QRS duration≥150ms MT ICD CRTD N/A Referent Ext Dominated £13,510 N/A 
NYHA III, QRS duration≥120ms and <150ms MT ICD CRTP CRTD Referent Dominated £12,071 £20,255 
NYHA III, QRS duration≥150ms MT ICD CRTP CRTD Referent Dominated £8,935 £22,075 
NYHA IV, QRS duration≥120ms and <150ms MT CRTP CRTD N/A Referent £17,519 £33,833 N/A 
NYHA IV, QRS duration≥150ms MT CRTP CRTD N/A Referent £13,733 £36,328 N/A 
a) Results in NYHA I and IV patients are based on relatively low patient numbers and may be subject to bias due to the nature of trial inclusion criteria for NYHA I patients. For 
further detail see main text.  
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Figure S1: Graphic display of cost-effective option across cost-effectiveness threshold values in patients with LBBB 
morphology (sensitivity analyses – constant all-cause mortality and HRQoL treatment effects) 
 
Panel a) patients without LBBB morphology 
 
Panel b) patients with LBBB morphology 
Legend: Results in NYHA I patients are based on relatively low patient numbers and may be subject to bias due 
to the nature of trial inclusion criteria for NYHA I patients. For further detail see main text.  
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